402 related articles for article (PubMed ID: 22343031)
21. Suppression of Ocular Vascular Inflammation through Peptide-Mediated Activation of Angiopoietin-Tie2 Signaling.
Mirando AC; Lima E Silva R; Chu Z; Campochiaro PA; Pandey NB; Popel AS
Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32708100
[TBL] [Abstract][Full Text] [Related]
22. Angiotensin AT(1) and AT(2) receptors differentially regulate angiopoietin-2 and vascular endothelial growth factor expression and angiogenesis by modulating heparin binding-epidermal growth factor (EGF)-mediated EGF receptor transactivation.
Fujiyama S; Matsubara H; Nozawa Y; Maruyama K; Mori Y; Tsutsumi Y; Masaki H; Uchiyama Y; Koyama Y; Nose A; Iba O; Tateishi E; Ogata N; Jyo N; Higashiyama S; Iwasaka T
Circ Res; 2001 Jan; 88(1):22-9. PubMed ID: 11139469
[TBL] [Abstract][Full Text] [Related]
23. Targeting the ANG2/TIE2 axis inhibits tumor growth and metastasis by impairing angiogenesis and disabling rebounds of proangiogenic myeloid cells.
Mazzieri R; Pucci F; Moi D; Zonari E; Ranghetti A; Berti A; Politi LS; Gentner B; Brown JL; Naldini L; De Palma M
Cancer Cell; 2011 Apr; 19(4):512-26. PubMed ID: 21481792
[TBL] [Abstract][Full Text] [Related]
24. Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2.
Oliner J; Min H; Leal J; Yu D; Rao S; You E; Tang X; Kim H; Meyer S; Han SJ; Hawkins N; Rosenfeld R; Davy E; Graham K; Jacobsen F; Stevenson S; Ho J; Chen Q; Hartmann T; Michaels M; Kelley M; Li L; Sitney K; Martin F; Sun JR; Zhang N; Lu J; Estrada J; Kumar R; Coxon A; Kaufman S; Pretorius J; Scully S; Cattley R; Payton M; Coats S; Nguyen L; Desilva B; Ndifor A; Hayward I; Radinsky R; Boone T; Kendall R
Cancer Cell; 2004 Nov; 6(5):507-16. PubMed ID: 15542434
[TBL] [Abstract][Full Text] [Related]
25. Angiopoietin-1 overexpression modulates vascular endothelium to facilitate tumor cell dissemination and metastasis establishment.
Holopainen T; Huang H; Chen C; Kim KE; Zhang L; Zhou F; Han W; Li C; Yu J; Wu J; Koh GY; Alitalo K; He Y
Cancer Res; 2009 Jun; 69(11):4656-64. PubMed ID: 19487284
[TBL] [Abstract][Full Text] [Related]
26. Vascular endothelial growth factor C disrupts the endothelial lymphatic barrier to promote colorectal cancer invasion.
Tacconi C; Correale C; Gandelli A; Spinelli A; Dejana E; D'Alessio S; Danese S
Gastroenterology; 2015 Jun; 148(7):1438-51.e8. PubMed ID: 25754161
[TBL] [Abstract][Full Text] [Related]
27. Angiopoietins assemble distinct Tie2 signalling complexes in endothelial cell-cell and cell-matrix contacts.
Saharinen P; Eklund L; Miettinen J; Wirkkala R; Anisimov A; Winderlich M; Nottebaum A; Vestweber D; Deutsch U; Koh GY; Olsen BR; Alitalo K
Nat Cell Biol; 2008 May; 10(5):527-37. PubMed ID: 18425119
[TBL] [Abstract][Full Text] [Related]
28. Fetoplacental regional variations in the expression of angiopoietin-1, angiopoietin-2, and Tie2 in normal-term and near-term pregnancies.
De A; Maulik D; Lankachandra K; Mundy DC; Ye SQ; Gerkovich MM
J Matern Fetal Neonatal Med; 2016 Nov; 29(21):3421-8. PubMed ID: 26752164
[TBL] [Abstract][Full Text] [Related]
29. Immunohistochemical demonstration of Angiopoietin-2 in lymphatic vascular development.
Shimoda H
Histochem Cell Biol; 2009 Feb; 131(2):231-8. PubMed ID: 18836739
[TBL] [Abstract][Full Text] [Related]
30. Effects of angiopoietins-1 and -2 on the receptor tyrosine kinase Tie2 are differentially regulated at the endothelial cell surface.
Hansen TM; Singh H; Tahir TA; Brindle NP
Cell Signal; 2010 Mar; 22(3):527-32. PubMed ID: 19922791
[TBL] [Abstract][Full Text] [Related]
31. Amelioration of sepsis by TIE2 activation-induced vascular protection.
Han S; Lee SJ; Kim KE; Lee HS; Oh N; Park I; Ko E; Oh SJ; Lee YS; Kim D; Lee S; Lee DH; Lee KH; Chae SY; Lee JH; Kim SJ; Kim HC; Kim S; Kim SH; Kim C; Nakaoka Y; He Y; Augustin HG; Hu J; Song PH; Kim YI; Kim P; Kim I; Koh GY
Sci Transl Med; 2016 Apr; 8(335):335ra55. PubMed ID: 27099174
[TBL] [Abstract][Full Text] [Related]
32. Angiopoietin-2: development of inhibitors for cancer therapy.
Hu B; Cheng SY
Curr Oncol Rep; 2009 Mar; 11(2):111-6. PubMed ID: 19216842
[TBL] [Abstract][Full Text] [Related]
33. Ligand oligomerization state controls Tie2 receptor trafficking and angiopoietin-2-specific responses.
Pietilä R; Nätynki M; Tammela T; Kangas J; Pulkki KH; Limaye N; Vikkula M; Koh GY; Saharinen P; Alitalo K; Eklund L
J Cell Sci; 2012 May; 125(Pt 9):2212-23. PubMed ID: 22357955
[TBL] [Abstract][Full Text] [Related]
34. 3-O-Acetyloleanolic acid inhibits angiopoietin-1-induced angiogenesis and lymphangiogenesis via suppression of angiopoietin-1/Tie-2 signaling.
Hwang-Bo J; Park JH; Chung IS
Phytother Res; 2020 Feb; 34(2):359-367. PubMed ID: 31680342
[TBL] [Abstract][Full Text] [Related]
35. Single chain Fv antibody against angiopoietin-2 inhibits VEGF-induced endothelial cell proliferation and migration in vitro.
Cai M; Zhang H; Hui R
Biochem Biophys Res Commun; 2003 Oct; 309(4):946-51. PubMed ID: 13679065
[TBL] [Abstract][Full Text] [Related]
36. G-CSF rescues tumor growth and neo-angiogenesis during liver metastasis under host angiopoietin-2 deficiency.
Im JH; Tapmeier T; Balathasan L; Gal A; Yameen S; Hill S; Smart S; Noterdaeme O; Kelly M; Brady M; Fu W; Kruse K; Bernhard EJ; Augustin HG; Muschel RJ
Int J Cancer; 2013 Jan; 132(2):315-26. PubMed ID: 22699974
[TBL] [Abstract][Full Text] [Related]
37. Angiopoietin-2 stimulates breast cancer metastasis through the alpha(5)beta(1) integrin-mediated pathway.
Imanishi Y; Hu B; Jarzynka MJ; Guo P; Elishaev E; Bar-Joseph I; Cheng SY
Cancer Res; 2007 May; 67(9):4254-63. PubMed ID: 17483337
[TBL] [Abstract][Full Text] [Related]
38. Utilizing combinatorial engineering to develop Tie2 targeting antagonistic angiopoetin-2 ligands as candidates for anti-angiogenesis therapy.
Shlamkovich T; Aharon L; Barton WA; Papo N
Oncotarget; 2017 May; 8(20):33571-33585. PubMed ID: 28422724
[TBL] [Abstract][Full Text] [Related]
39. Angiopoietin 2 alters pancreatic vascularization in diabetic conditions.
Calderari S; Chougnet C; Clemessy M; Kempf H; Corvol P; Larger E
PLoS One; 2012; 7(1):e29438. PubMed ID: 22272235
[TBL] [Abstract][Full Text] [Related]
40. A heparin conjugate, LHbisD4, inhibits lymphangiogenesis and attenuates lymph node metastasis by blocking VEGF-C signaling pathway.
Choi JU; Chung SW; Al-Hilal TA; Alam F; Park J; Mahmud F; Jeong JH; Kim SY; Byun Y
Biomaterials; 2017 Sep; 139():56-66. PubMed ID: 28586719
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
